Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease

被引：55

作者：

Geldenhuys, Werner J. ^{[1
]}

Van der Schyf, Cornelis J. ^{[1
]}

机构：

[1] Northeastern Ohio Univ Coll Med & Pharm, Dept Pharmaceut Sci, Rootstown, OH 44272 USA

来源：

CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2008年 / 8卷 / 12期

关键词：

QSAR; G-coupled protein receptor; GCPR; tryptamine; arylsulfonyl; multifunctional; dementia;

D O I：

10.2174/156802608785161420

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Recently, the serotonin 5-HT6 receptor has been identified as a drug target for attenuating cognitive deficits associated with Alzheimer's disease ( AD). Additionally, this receptor may also play a role in schizophrenia, anxiety and obesity. Reports in the literature suggest that the production of selective antagonists for the 5-HT6 receptor has increased during the last 10 years, with some compounds currently in clinical trials for the treatment of AD. In this review, we will address the rationale for using 5-HT6 receptor antagonists in AD, as well as report on current advances in the understanding of the structure-activity relationships required to synthesize 5-HT6 receptor antagonists.

引用

页码：1035 / 1048

页数：14

共 72 条

[1] Interaction of chiral MS-245 analogs at h5-HT6 receptors [J].

Abate, C ;

Kolanos, R ;

Dukat, M ;

Setola, V ;

Roth, BL ;

Glennon, RA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (15) :3510-3513

[2] Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site [J].

Akk, G ;

Steinbach, JH .

JOURNAL OF NEUROSCIENCE, 2005, 25 (08) :1992-2001

[3] Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats [J].

Bentley, JC ;

Bourson, A ;

Boess, FG ;

Fone, KCF ;

Marsden, CA ;

Petit, N ;

Sleight, AJ .

BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (07) :1537-1542

[4] 1-(2-aminoethyl)-3-(arylsulfonyl)-1H-indoles as novel 5-HT6 receptor ligands [J].

Bernotas, R ;

Lenicek, S ;

Antane, S ;

Zhang, GM ;

Smith, D ;

Coupet, J ;

Harrison, B ;

Schechter, LE .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (22) :5499-5502

[5] Molecular pathways to neurodegeneration [J].

Bossy-Wetzel, E ;

Schwarzenbacher, R ;

Lipton, SA .

NATURE MEDICINE, 2004, 10 (07) :S2-S9

[6] Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset [J].

Brookmeyer, R ;

Gray, S ;

Kawas, C .

AMERICAN JOURNAL OF PUBLIC HEALTH, 1998, 88 (09) :1337-1342

[7] 1,2,3,4-tetrahydrocarbazoles as 5-HT6 serotonin receptor ligands [J].

Chang-Fong, J ;

Rangisetty, JB ;

Dukat, M ;

Setola, V ;

Raffay, T ;

Roth, B ;

Glennon, RA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (08) :1961-1964

[8] The chemical biology of clinically tolerated NMDA receptor antagonists [J].

Chen, Huei-Sheng Vincent ;

Lipton, Stuart A. .

JOURNAL OF NEUROCHEMISTRY, 2006, 97 (06) :1611-1626

[9] Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists [J].

Cole, DC ;

Lennox, WJ ;

Stock, JR ;

Ellingboe, JW ;

Mazandarani, H ;

Smith, DL ;

Zhang, GM ;

Tawa, GJ ;

Schechter, LE .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (21) :4780-4785

[10] CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists [J].

Doddareddy, MR ;

Cho, YS ;

Koh, HY ;

Pae, AN .

BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (15) :3977-3985

← 1 2 3 4 5 6 7 8 →